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Abstract
Background: Randomised trials comparing different drugs head-to-head are extremely valuable for
clinical decision-making. However, it is scientifically and ethically sensible to demand strong evidence that
a drug is effective by showing superiority over a placebo before embarking on head-to-head comparisons
of potentially ineffective drugs. Our aim was to study the evolvement of evidence from placebo-controlled
and head-to-head trials on the effects of antibiotics for the treatment of mild to moderate exacerbations
of chronic obstructive pulmonary disease.
Methods: We conducted a historical systematic review. Through electronic databases and hand-searches,
we identified placebo-controlled and head-to-head antibiotic trials for the treatment of mild to moderate
chronic obstructive pulmonary disease exacerbations. We compared the numbers of patients recruited in
placebo-controlled and head-to-head trials between 1957 and 2005. Using cumulative meta-analysis of
placebo-controlled trials, we determined when, if ever, placebo-controlled trials had shown convincing
evidence that antibiotics are effective in preventing treatment failure in patients with mild to moderate
chronic obstructive pulmonary disease exacerbations.
Results:  The first head-to-head trial was published in 1963. It was followed by another 100 trials
comparing different antibiotics in a total of 34,029 patients with mild to moderate chronic obstructive
pulmonary disease exacerbations. Over time, the cumulative odds ratio in placebo-controlled trials
remained inconclusive throughout with odds ratios ranging from 0.39 (95% confidence intervals 0.04–4.22)
to the most recent estimate (1995) of 0.81 (95% confidence intervals 0.52–1.28, P = 0.37).
Conclusion:  Placebo-controlled trials do not support the use of antibiotics in chronic obstructive
pulmonary disease patients with mild to moderate exacerbations. Conducting head-to-head trials is,
therefore, scientifically and ethically questionable. This underscores the requirement to perform or study
systematic reviews of placebo-controlled trials before conducting head-to-head trials.
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Background
The Helsinki Declaration emphasises the great impor-
tance of conducting experimental studies for medical
progress. However, it also states that one should be very
careful before embarking on randomised trials with pla-
cebo controls because research participants have a right to
the best available treatment [1]. Worries about the
'unethical use of placebo' continue [2,3]. However, what
about the reverse scenario? Might there be cases where
experimental treatment did not show superiority over pla-
cebo but where the placebo controls were abandoned nev-
ertheless, thus exposing patients to adverse effects and
society to healthcare expenditures not offset by any bene-
ficial effects?
There is a large number randomised trials comparing dif-
ferent antibiotics (without placebo control) for the treat-
ment of exacerbations of chronic obstructive pulmonary
disease (COPD). Although it may seem plausible that
antibiotics are beneficial in about 50% of the COPD
patients in whom bacteria are the cause of the exacerba-
tion [4], there is evidence indicating that antibiotics have
a short-term effect only in COPD patients with severe
exacerbations but not in mild to moderate exacerbations
[5]. Although head-to-head comparisons of different
treatment options available in clinical practice can be very
useful [6], an underlying assumption of such trials is that
the treatments are effective compared with a placebo [7-
9]. While conducting a series of systematic reviews of
treatments in COPD, we gained the impression that the
evaluation of antibiotics for COPD exacerbations had
moved to head-to-head comparisons of different antibiot-
ics with very little research in placebo-controlled trials. We
set out to test this hypothesis in a more systematic way.
We counted the number of randomised trials of antibiotic
treatment for mild to moderate exacerbations in COPD
patients published in the last 50 years, determined
whether they used a placebo control or conducted head-
to-head comparisons, and contrasted the number of
patients studied with the results of a cumulative meta-
analysis, using data from a recently published systematic
review.
Methods
Data sources and searches
For the identification of antibiotics trials in COPD
patients, we used a comprehensive literature search
described elsewhere [5]. In brief, information specialists
(Bazian, London, UK, http://www.bazian.com) searched
the Cochrane Central Register of Controlled Trials (CEN-
TRAL, 2005 issue 4), PREMEDLINE (1960 to 1965),
MEDLINE (1966 to March 2006), EMBASE (1974 to
March 2006), the Database of Abstracts of Reviews of
Effects (DARE, March 2006) for any randomised trials on
antibiotics in COPD patients. Two reviewers independ-
ently assessed the titles and abstracts of all the identified
citations without imposing any language restrictions. The
full text of any article that seemed potentially eligible by
one of the reviewers was ordered. The reviewers then eval-
uated the full text of retrieved articles and selected those
meeting the inclusion criteria. Each reviewer's decisions
were recorded in the Endnote file and any disagreements
were resolved by consensus.
Study selection
We included randomised head-to-head trials comparing
any antibiotics or an antibiotic with placebo for the treat-
ment of mild to moderate exacerbations in COPD
patients. Placebo-controlled trials allow for an estimation
of the specific effects of the treatment and offer a proof of
effectiveness [7].
As with any systematic review on this topic, a difficulty is
that definitions of COPD have varied over time. In partic-
ular, spirometry criteria became widespread only after
1995 and we accepted a clinical diagnosis of COPD,
chronic bronchitis or emphysema. However, in order to
include only trials whose patients were very likely to have
COPD, we included studies only if patients with chronic
bronchitis were at least 40 years of age and/or if at least
80% were smokers or ex-smokers. The presence of these
characteristics (chronic bronchitis, age and smoking his-
tory) renders a diagnosis of COPD according to modern
(spirometric) criteria extremely likely [10]. We defined
patients to have 'mild to moderate exacerbations' if they
needed any outpatient treatment (level I exacerbation)
according to the Operational Classification of Severity of
the European Respiratory and American Thoracic Socie-
ties [11].
Data extraction and analysis
For each trial, one reviewer recorded details about the type
of trial (placebo-controlled or head-to-head), year of pub-
lication and number of included patients. A second
reviewer checked data extraction for correctness. We calcu-
lated the cumulative number of patients included in these
trials over the years. We plotted the cumulative number of
patients against the year of publication. A systematic
review of the placebo-controlled trials has been reported
elsewhere [5]. We conducted a cumulative meta-analysis
of the effects of antibiotics on treatment failure, com-
monly used as the main outcome, using the set of pla-
cebo-controlled trials. With the cumulative meta-analysis
we determined when, if ever, placebo-controlled trials
had shown convincing evidence that antibiotics were
effective in preventing treatment failure in mild to moder-
ate exacerbations. Thus the cumulative meta-analysis
showed what the state of knowledge would have been if
people had reviewed the published literature. In a sensi-
tivity analysis, we included another trial [12] that we, asBMC Medicine 2008, 6:28 http://www.biomedcentral.com/1741-7015/6/28
Page 3 of 6
(page number not for citation purposes)
reported previously [5], excluded from the main analyses
because we had major doubts about the reported results.
We were interested in whether inclusion of this trial
changed the cumulative odds ratio (OR) significantly. We
conducted all analyses in STATA for windows version 9.2
(Stata Corp; College Station, TX, US).
Results
Placebo-controlled and head-to-head trials
Out of 15 placebo-controlled trials, seven enrolled outpa-
tients with mild to moderate exacerbations. We identified
a total of 212 head-to-head trials, of which 101 explicitly
enrolled outpatients with mild to moderate exacerbations
and 63 enrolled inpatients. In 48 trials, patients with any
severity of exacerbations were enrolled or severity of the
exacerbation could not be determined.
Figure 1 shows the cumulative number of placebo-con-
trolled and head-to-head trials as well as the number of
enrolled patients between 1957 and 2005. Over this
period of almost 50 years, the 101 head-to-head trials
enrolled a total of 34,029 patients with mild to moderate
exacerbations.
The first head-to-head trial in 1963 [13] included patients
with mild to moderate exacerbations and compared sul-
phonamide with penicillin, with the aim of finding an
antibiotic with fewer adverse events than oxytetracycline,
the drug used in the three earlier placebo-controlled trials
[14-16]. As in many of the following head-to-head trials
[17], the role of the antibiotic itself was not questioned. A
common reason to justify a head-to-head trial was that
antibiotics are effective against organisms most com-
monly associated with purulent sputum in chronic bron-
chitis, such as Haemophilus influenzae and  Streptococcus
pneumoniae. Thus rather than citing evidence from pla-
cebo-controlled trials, they referred to the in-vitro activity
of antibiotics (for example [18,19]). Yet another group of
head-to-head trials referred to placebo-controlled trials to
justify their head-to-head trials but selectively cited only
those trials with positive results [20,21].
Evidence on the effects of antibiotics in mild to moderate 
COPD exacerbations
The seven trials included a total of 990 outpatients with
mild to moderate exacerbations. Figure 2 shows the
cumulative meta-analyses for the five trials reporting on
treatment failure. In one trial, treatment failure was
defined as event-based because of the need for further
antibiotics [15] and in four trials, a symptom-based defi-
nition of treatment failure was used [14,22-24]. Cumula-
tive ORs never reached statistical significance and the
most recent (1995) cumulative OR was 0.81 (95% confi-
dence interval (CI) 0.52–1.28, P = 0.37). When we also
Number of patients in antibiotic trials Figure 1
Number of patients in antibiotic trials. Cumulative number of patients with chronic obstructive pulmonary disease 
enrolled in placebo-controlled and head-to-head trials evaluating antibiotics in patients with mild to moderate exacerbations 
from the first published trials until 2005.
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included another trial [12], as explained above, the cumu-
lative OR also remained non-significant (0.50, 95% CI
0.20–1.24, P = 0.14). In other words, cumulative evidence
from placebo-controlled trials did not show any signifi-
cant effects of antibiotics on treatment failure in COPD
patients with mild to moderate exacerbations.
The rationale for the first placebo-controlled trials was
reported to be the uncertainty about the benefits of a
'short course' of 'intermittent' antibiotic therapy for exac-
erbations [14-16]. The authors explicitly stated the short
duration of antibiotic treatment because prophylactic
long-term use of antibiotics to prevent exacerbations was
quite common at that time [25]. Over the following 40
years, authors of placebo-controlled trials argued that
these trials are required because 'the role of the [antibi-
otic] therapy is not clear' [22], or because 'it is still not suf-
ficiently clarified whether acute exacerbations of chronic
bronchitis should be treated with antibiotics' [23]. These
statements reflect the ongoing debate about the useful-
ness of antibiotics for COPD exacerbations.
Discussion
Our historical analysis showed that many head-to-head
trials of antibiotics for mild to moderate COPD exacerba-
tions have been conducted although evidence from ran-
domised placebo-controlled trials never showed that
antibiotics were effective at all. So, in this case, the evalu-
ation of antibiotics did not follow the general principle
that placebo-controlled trials must have shown that the
treatment is better than the placebo or a sham procedure,
before head-to-head trials are to be conducted [9].
Our study has some strengths and limitations. We used a
comprehensive literature search to identify trials. The
selection of a widely prescribed drug for a major disease
makes our 'case report' meaningful, because we could
base our historical analysis on a large number of trials. A
limitation of systematic reviews in COPD is the evolution
of definitions and classifications of COPD over the years.
This raises uncertainty about the nature of the study pop-
ulations included in trials published before 1995 or even
before 2000. Many trials included patients with 'chronic
bronchitis' who did not present evidence of chronic air-
flow obstruction or poor reversibility of airflow obstruc-
tion.
It should be emphasised that the results of this study
apply to antibiotic treatment for mild to moderate COPD
exacerbations. In patients with severe exacerbations, anti-
Evidence on the effects of antibiotics in chronic obstructive pulmonary disease exacerbations Figure 2
Evidence on the effects of antibiotics in chronic obstructive pulmonary disease exacerbations. Cumulative meta-
analyses of placebo-controlled trials, which evaluated the effects of antibiotics on treatment failure in patients with mild to 
moderate exacerbations.
Figure 2
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Sachs 1995 1.06 (0.18-6.30) 0.81 (0.52-1.28), p=0.37
Jorgensen 1992 1.05 (0.64-1.72) 0.76 (0.42-1.36), p=0.36
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biotics show a strong effect not only on treatment failure
but also on mortality [5]. Our analysis of placebo-control-
led trials differs to some extent to that of the Cochrane
review [26] because we did not include a study [27] that
was not a randomised but, in our opinion, a matched con-
trolled study. However, we included the trial by Sachs et
al [24] missed by the Cochrane review and received the
original data from the authors. However, the Cochrane
review [26] also showed that antibiotics have a significant
effect on treatment failure in hospitalised patients but not
in outpatients.
We have focused in our analysis on one major treatment
for COPD patients. It remains unclear if head-to-head tri-
als are conducted frequently in other areas without an evi-
dence base from placebo-controlled trials. It is
conceivable that this example of antibiotics is just the tip
of the iceberg. A recent systematic review summarised pla-
cebo-controlled and head-to-head trials of exercise for low
back pain [28]. Head-to-head trials were conducted over
the same period of time as the placebo-controlled trials.
The same applies to trials evaluating antidepressants for
elderly people [29,30] or antibiotics for acute otitis media
in children [31,32]. For these widely prescribed treat-
ments for common conditions, it remains as yet uncertain
whether the conduct of head-to-head trials was scientifi-
cally and ethically justified.
Further studies are warranted to estimate the magnitude
of the phenomenon that conduct of head-to-head trials is
not solidly based on evidence from placebo-controlled tri-
als. It is unclear why investigators rarely refer to existing
systematic reviews to justify their trials scientifically and
ethically, although access to such systematic reviews has
become so easy [33]. We also need to find out what trig-
gers investigators to conduct head-to-head trials too early.
The reports on head-to-head trials on antibiotics shed
some light on this tendency. High plausibility that an
intervention works may be one of the most important rea-
sons. For antibiotics, evidence is available about their in-
vitro  activity against the bacteria commonly found in
COPD exacerbations. Intuitively, one may extrapolate this
to the clinical situation. Physicians are also confirmed in
their habit of antibiotic prescription because most outpa-
tients with mild to moderate exacerbations recover within
2 weeks. Yet they do not seem to be aware of the 'natural'
recovery rate (that is, without antibiotics) in these
patients, which is 80% or more and equal to that in
patients receiving placebo [5].
In general, the pharmaceutical industry tends to favour
placebo-controlled trials in order to show large effects and
to avoid direct comparison with competitors. In situations
like this, however, where comparisons with placebo do
not favour a drug, the pharmaceutical industry might be
more interested in head-to-head trials. Once a treatment,
such as antibiotics for COPD exacerbations, is established
in clinical practice an attractive market is available. If a
company wants to enter this market it needs to provide a
trial showing clinical non-inferiority of a new antibiotic
and some advantages in terms of adverse effects or costs.
Hence, chance aside, even a new antibiotic lacking specific
activity will not be inferior to any established antibiotic in
COPD outpatients. This will make it relatively easy to get
approval from regulatory agencies, as long as the drug is
safe.
As mentioned above, placebo-controlled trials continue
to be conducted even if the effectiveness of a drug has
been definitively established. Fergusson et al [2] provided
an impressive example on that problem recently. They
identified all comparisons of aprotinin, which limits peri-
operative bleeding and reduces the need for blood trans-
fusions, with a placebo. After 12 placebo-controlled trials,
the effect estimates stabilised at a cumulative OR of 0.25
for the need for blood transfusions favouring aprotinin.
Nevertheless, another 52 randomised placebo-controlled
trials were conducted although that was ethically not jus-
tifiable [3]. These trials cited previous randomised con-
trolled trials very poorly so that readers were not aware
that the question had been answered definitively by previ-
ous trials.
The unjustified conduct of placebo-controlled or head-to-
head trials can be prevented if funding bodies and ethical
committees ask investigators to present a systematic
review that justifies a new trial. Such systematic reviews
are often available already, for example, published by the
Cochrane Collaboration. If not, investigators need to
carry out a systematic review themselves and publish it
regardless of the findings in order to stimulate a public
discussion about the need for new trials. Uncertainty
about the effectiveness of a treatment should be discussed
openly because it may also encourage patients and physi-
cians to participate in a new trial.
Conclusion
Our historical analysis showed that the evaluation of anti-
biotics for mild to moderate COPD exacerbations has
been far from optimal. Head-to-head trials have been con-
ducted without any supporting evidence from placebo-
controlled trials. This phenomenon raises important sci-
entific and ethical concerns and more studies are war-
ranted to find out its prevalence, mechanisms and
consequences in medicine. In the meantime, public fund-
ing bodies and ethical committees in particular should
encourage the careful conduct or study of pertinent sys-
tematic reviews before supporting the conduct of new tri-
als.BMC Medicine 2008, 6:28 http://www.biomedcentral.com/1741-7015/6/28
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